Provision of iQue Screening Platform
Details
- Supplier(s)
- IntelliCyt Corporation
- Value
- GBP 200,000
- Duration
- 5 years
- Topic
- Cytometers
- Published
- 16 February 2017
- Source
- ContractsFinder
Tender description
TB Research Group, National Infection Service, Public Health England (PHE) awarded a contract for the provision of iQue screening platform merging high throughput screening with high content flow cytometry to IntelliCyt Corporation. This purchase is to support the screening of antimicrobial activity on current and novel drugs against Mycobacterium tuberculosis. The iQue Plus Screener is the only instrument on the market capable of the speeds required for this work, as it can analyse samples from a full 96-well plate in
Timeline
- Completed: Award published16 February 2017Current notice
- Completed: Award date16 February 2017
- Completed: Contract expiry date15 February 2022
About the buyer
Public Health England is a public sector buyer in United Kingdom publishing tenders and awards on Stotles. Explore their procurement activity and find more opportunities like this one.
Relevant CPV codes
- 38434510 · Cytometers
Decision makers
Connect with the people behind this procurement.
| Contact name | Job title | Phone number | Work email |
|---|---|---|---|
| Head of Procurement | +44 •••• •••••• | ••••••••@public-health-england.gov | |
| Commercial Director | +44 •••• •••••• | ••••••••@public-health-england.gov | |
| Procurement Manager | +44 •••• •••••• | ••••••••@public-health-england.gov | |
| Category Lead | +44 •••• •••••• | ••••••••@public-health-england.gov | |
| Senior Buyer | +44 •••• •••••• | ••••••••@public-health-england.gov | |
| Contracts Manager | +44 •••• •••••• | ••••••••@public-health-england.gov |
Related buyers
Buyers similar to Public Health England.
- 2,594£1.6bn
- 1,683£204.6bn
- 880£19.4bn
- 677£8.8bn
- 461£15.4bn
- 423£3.8bn
- 339£20.2m
- 290£366.8m
- 256£233.2m
- 252£892.4m
Win more public sector contracts
Track every UK and Ireland tender in one place — set up alerts, find decision-makers, and never miss an opportunity.
